Show simple item record

dc.contributor.authorStrasburger, CJen_US
dc.contributor.authorKaravitaki, Nen_US
dc.contributor.authorStörmann, Sen_US
dc.contributor.authorTrainer, PJen_US
dc.contributor.authorKreitschmann-Andermahr, Ien_US
dc.contributor.authorDroste, Men_US
dc.contributor.authorKorbonits, Men_US
dc.contributor.authorFeldmann, Ben_US
dc.contributor.authorZopf, Ken_US
dc.contributor.authorSanderson, VFen_US
dc.contributor.authorSchwicker, Den_US
dc.contributor.authorGelbaum, Den_US
dc.contributor.authorHaviv, Aen_US
dc.contributor.authorBidlingmaier, Men_US
dc.contributor.authorBiermasz, NRen_US
dc.date.accessioned2016-06-07T12:37:42Z
dc.date.available2015-12-17en_US
dc.date.issued2016-03en_US
dc.date.submitted2016-06-06T18:28:12.739Z
dc.identifier.other10.1530/EJE-15-1042
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/12718
dc.descriptionThis work is licensed under a Creative Commons Attribution 3.0 Unported Licenseen_US
dc.description.abstractBACKGROUND: Long-acting somatostatin analogues delivered parenterally are the most widely used medical treatment in acromegaly. This patient-reported outcomes survey was designed to assess the impact of chronic injections on subjects with acromegaly. METHODS: The survey was conducted in nine pituitary centres in Germany, UK and The Netherlands. The questionnaire was developed by endocrinologists and covered aspects of acromegaly symptoms, injection-related manifestations, emotional and daily life impact, treatment satisfaction and unmet medical needs. RESULTS: In total, 195 patients participated, of which 112 (57%) were on octreotide (Sandostatin LAR) and 83 (43%) on lanreotide (Somatuline Depot). The majority (>70%) of patients reported acromegaly symptoms despite treatment. A total of 52% of patients reported that their symptoms worsen towards the end of the dosing interval. Administration site pain lasting up to a week following injection was the most frequently reported injection-related symptom (70% of patients). Other injection site reactions included nodules (38%), swelling (28%), bruising (16%), scar tissue (8%) and inflammation (7%). Injection burden was similar between octreotide and lanreotide. Only a minority of patients received injections at home (17%) and 5% were self-injecting. Over a third of patients indicated a feeling of loss of independence due to the injections, and 16% reported repeated work loss days. Despite the physical, emotional and daily life impact of injections, patients were satisfied with their treatment, yet reported that modifications that would offer major improvement over current care would be 'avoiding injections' and 'better symptom control'. CONCLUSION: Lifelong injections of long-acting somatostatin analogues have significant burden on the functioning, well-being and daily lives of patients with acromegaly.en_US
dc.description.sponsorshipChiasma, Inc. 60 Welles Ave, Newton, MA 02 459, USA.en_US
dc.format.extent355 - 362en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofEur J Endocrinolen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectAcromegalyen_US
dc.subjectAdenomaen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAntineoplastic Agents, Hormonalen_US
dc.subjectCost of Illnessen_US
dc.subjectDelayed-Action Preparationsen_US
dc.subjectFemaleen_US
dc.subjectGermanyen_US
dc.subjectGrowth Hormone-Secreting Pituitary Adenomaen_US
dc.subjectHumansen_US
dc.subjectInjections, Intramuscularen_US
dc.subjectInjections, Subcutaneousen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectNetherlandsen_US
dc.subjectOctreotideen_US
dc.subjectPatient Outcome Assessmenten_US
dc.subjectPatient Satisfactionen_US
dc.subjectPeptides, Cyclicen_US
dc.subjectSelf Reporten_US
dc.subjectSomatostatinen_US
dc.subjectSurveys and Questionnairesen_US
dc.subjectTreatment Outcomeen_US
dc.subjectYoung Adulten_US
dc.titlePatient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.en_US
dc.typeArticle
dc.rights.holderCopyright: © 2016 The authors
dc.identifier.doi10.1530/EJE-15-1042en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/26744896en_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume174en_US
dcterms.dateAccepted2015-12-17en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States